319 related articles for article (PubMed ID: 34122413)
1. Comprehensive Comparison of RNA-Seq Data of SARS-CoV-2, SARS-CoV and MERS-CoV Infections: Alternative Entry Routes and Innate Immune Responses.
Cao Y; Xu X; Kitanovski S; Song L; Wang J; Hao P; Hoffmann D
Front Immunol; 2021; 12():656433. PubMed ID: 34122413
[TBL] [Abstract][Full Text] [Related]
2. Innate Immune Responses to Highly Pathogenic Coronaviruses and Other Significant Respiratory Viral Infections.
Ahmed-Hassan H; Sisson B; Shukla RK; Wijewantha Y; Funderburg NT; Li Z; Hayes D; Demberg T; Liyanage NPM
Front Immunol; 2020; 11():1979. PubMed ID: 32973803
[TBL] [Abstract][Full Text] [Related]
3. Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past.
Shah VK; Firmal P; Alam A; Ganguly D; Chattopadhyay S
Front Immunol; 2020; 11():1949. PubMed ID: 32849654
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Immune Response between SARS, MERS, and COVID-19 Infection, Perspective on Vaccine Design and Development.
Ansariniya H; Seifati SM; Zaker E; Zare F
Biomed Res Int; 2021; 2021():8870425. PubMed ID: 33564683
[TBL] [Abstract][Full Text] [Related]
5. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
6. Interaction of SARS and MERS Coronaviruses with the Antiviral Interferon Response.
Kindler E; Thiel V; Weber F
Adv Virus Res; 2016; 96():219-243. PubMed ID: 27712625
[TBL] [Abstract][Full Text] [Related]
7. The lethal internal face of the coronaviruses: Kidney tropism of the SARS, MERS, and COVID19 viruses.
Motavalli R; Abdelbasset WK; Rahman HS; Achmad MH; Sergeevna NK; Zekiy AO; Adili A; Khiavi FM; Marofi F; Yousefi M; Ghoreishizadeh S; Shomali N; Etemadi J; Jarahian M
IUBMB Life; 2021 Aug; 73(8):1005-1015. PubMed ID: 34118117
[TBL] [Abstract][Full Text] [Related]
8. Topological Analysis for Sequence Variability: Case Study on more than 2K SARS-CoV-2 sequences of COVID-19 infected 54 countries in comparison with SARS-CoV-1 and MERS-CoV.
Sarkar JP; Saha I; Seal A; Maity D; Maulik U
Infect Genet Evol; 2021 Mar; 88():104708. PubMed ID: 33421654
[TBL] [Abstract][Full Text] [Related]
9. Comparative Study of SARS-CoV-2, SARS-CoV-1, MERS-CoV, HCoV-229E and Influenza Host Gene Expression in Asthma: Importance of Sex, Disease Severity, and Epithelial Heterogeneity.
Coden ME; Loffredo LF; Abdala-Valencia H; Berdnikovs S
Viruses; 2021 Jun; 13(6):. PubMed ID: 34198852
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 infection mediates differential expression of human endogenous retroviruses and long interspersed nuclear elements.
Marston JL; Greenig M; Singh M; Bendall ML; Duarte RRR; Feschotte C; Iñiguez LP; Nixon DF
JCI Insight; 2021 Dec; 6(24):. PubMed ID: 34731091
[TBL] [Abstract][Full Text] [Related]
11. Overview of lethal human coronaviruses.
Chen B; Tian EK; He B; Tian L; Han R; Wang S; Xiang Q; Zhang S; El Arnaout T; Cheng W
Signal Transduct Target Ther; 2020 Jun; 5(1):89. PubMed ID: 32533062
[TBL] [Abstract][Full Text] [Related]
12. A comparative review of pathogenesis and host innate immunity evasion strategies among the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV).
Noor R
Arch Microbiol; 2021 Jul; 203(5):1943-1951. PubMed ID: 33682075
[TBL] [Abstract][Full Text] [Related]
13. Product of natural evolution (SARS, MERS, and SARS-CoV-2); deadly diseases, from SARS to SARS-CoV-2.
Shahrajabian MH; Sun W; Cheng Q
Hum Vaccin Immunother; 2021 Jan; 17(1):62-83. PubMed ID: 32783700
[TBL] [Abstract][Full Text] [Related]
14. LY6E impairs coronavirus fusion and confers immune control of viral disease.
Pfaender S; Mar KB; Michailidis E; Kratzel A; Boys IN; V'kovski P; Fan W; Kelly JN; Hirt D; Ebert N; Stalder H; Kleine-Weber H; Hoffmann M; Hoffmann HH; Saeed M; Dijkman R; Steinmann E; Wight-Carter M; McDougal MB; Hanners NW; Pöhlmann S; Gallagher T; Todt D; Zimmer G; Rice CM; Schoggins JW; Thiel V
Nat Microbiol; 2020 Nov; 5(11):1330-1339. PubMed ID: 32704094
[TBL] [Abstract][Full Text] [Related]
15. Elevated temperature inhibits SARS-CoV-2 replication in respiratory epithelium independently of IFN-mediated innate immune defenses.
Herder V; Dee K; Wojtus JK; Epifano I; Goldfarb D; Rozario C; Gu Q; Da Silva Filipe A; Nomikou K; Nichols J; Jarrett RF; Stevenson A; McFarlane S; Stewart ME; Szemiel AM; Pinto RM; Masdefiol Garriga A; Davis C; Allan J; Graham SV; Murcia PR; Boutell C
PLoS Biol; 2021 Dec; 19(12):e3001065. PubMed ID: 34932557
[TBL] [Abstract][Full Text] [Related]
16. Comparative pathology, molecular pathogenicity, immunological features, and genetic characterization of three highly pathogenic human coronaviruses (MERS-CoV, SARS-CoV, and SARS-CoV-2).
Rabaan AA; Mutair AA; Alawi ZA; Alhumaid S; Mohaini MA; Aldali J; Tirupathi R; Sule AA; Koritala T; Adhikari R; Bilal M; Dhawan M; Mohapatra RK; Tiwari R; Sami SA; Mitra S; Pandey MK; Harapan H; Emran TB; Dhama K
Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7162-7184. PubMed ID: 34859882
[TBL] [Abstract][Full Text] [Related]
17. The Immune Responses against Coronavirus Infections: Friend or Foe?
Vafaeinezhad A; Atashzar MR; Baharlou R
Int Arch Allergy Immunol; 2021; 182(9):863-876. PubMed ID: 33951640
[TBL] [Abstract][Full Text] [Related]
18. Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2.
Zhang XY; Huang HJ; Zhuang DL; Nasser MI; Yang MH; Zhu P; Zhao MY
Infect Dis Poverty; 2020 Jul; 9(1):99. PubMed ID: 32690096
[TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 infection activates a subset of intrinsic pathways to inhibit type I interferons
Luo W; Huang L; Wang X; Ma Y; Xiao J; Song X; Liu P; Wang Y; Wang Y; Ren Z
Int J Med Sci; 2021; 18(12):2561-2569. PubMed ID: 34104087
[TBL] [Abstract][Full Text] [Related]
20. Innate Immune Signaling and Proteolytic Pathways in the Resolution or Exacerbation of SARS-CoV-2 in Covid-19: Key Therapeutic Targets?
Sallenave JM; Guillot L
Front Immunol; 2020; 11():1229. PubMed ID: 32574272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
